Acquisition

Dechra Pharmaceuticals PLC 21 December 2006 Issued by Citigate Dewe Rogerson, Birmingham Date: Thursday 21st December 2006 Embargoed: 7.00am Dechra Pharmaceuticals PLC Dechra acquires worldwide Intellectual Property Rights to Equidone Dechra Pharmaceuticals PLC ('Dechra' or 'the Group') today announces that the Group has acquired the intellectual property for Equidone, an equine product from Equi-Tox(R) Inc., a US Company. The use of the active ingredient, Domperidone, has been co-developed by Equi-Tox and Clemson University, based in South Carolina, USA for the prevention of Fescue Toxicity. The consideration for the intellectual property is US$1.75 million payable in cash, of which US$0.5 million has been paid on completion. The remaining balance will be paid following licensing approval by the FDA, with submission being targeted in 2008. In addition, the Group will pay future royalties of 10% on revenues received. Equidone is already patented and under limited distribution in the US under a special license. The market for equine fescue toxicity is estimated to be approximately US$2 million per annum. Other patents for Equidone use have also been approved; evaluation of other indications with substantially larger markets will commence in 2007. Ian Page, Chief Executive, Dechra Pharmaceuticals PLC commented: 'Development of the Group's international veterinary pharmaceutical portfolio is important to our future growth; therefore we are delighted to have acquired the intellectual property for this product. The North American market is of importance to our strategy as it is the largest companion animal market in the world'. Enquiries: Ian Page, Chief Executive Fiona Tooley, Director Simon Evans, Group Finance Director Katie Dale, Senior Account Manager Dechra Pharmaceuticals PLC Citigate Dewe Rogerson Telephone: 01782 771 100 Telephone: 0121 455 8370 www.dechra.com Further information on Equi-Tox Inc. can be found at www.equitox.com Editors Note: Fescue toxicity is caused by eating a fungus which infects tall fescue grass. The most serious clinical signs are observed in the late stages of pregnancy and the toxicity can result in foal death. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings